Cleared Traditional

ARCHITECT I THEOPHYLLINE REAGENTS AND CALIBRATORS (A-F) (K070810) - FDA 510(k) Clearance

Class II Toxicology device cleared through predicate-based substantial equivalence - typically does not require clinical trials.

K070810 · Biokit, S.A. · Toxicology device
Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Jun 2007
Decision
74d
Days
Class 2
Risk

K070810 is an FDA 510(k) clearance for the ARCHITECT I THEOPHYLLINE REAGENTS AND CALIBRATORS (A-F). Classified as Fluorescence Polarization Immunoassay, Theophylline (product code LGS), Class II - Special Controls.

Submitted by Biokit, S.A. (Barcelona, ES). The FDA issued a Cleared decision on June 8, 2007 after a review of 74 days - a notably fast clearance cycle.

This device falls under the Toxicology FDA review panel, regulated under 21 CFR 862.3880 - the FDA toxicology device framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: Fast-track predicate clearance. Standard predicate reliance. The short review cycle indicates strong predicate alignment - the FDA found sufficient equivalence without extended technical review.

View all Biokit, S.A. devices

Submission Details

510(k) Number K070810 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received March 26, 2007
Decision Date June 08, 2007
Days to Decision 74 days
Submission Type Traditional
Review Panel Toxicology (TX)
Summary Summary PDF
Third-party Review No - reviewed directly by FDA
Regulatory Context
Review time vs. panel average
13d faster than avg
Panel avg: 87d · This submission: 74d
Pathway characteristics
Predicate-based equivalence. No clinical trials required.

Device Classification

Product Code LGS Fluorescence Polarization Immunoassay, Theophylline
Device Class Class 2 - Special Controls
CFR Regulation 21 CFR 862.3880
What this classification means

Class II devices require demonstration of substantial equivalence to a legally marketed predicate device. This pathway does not require clinical trials - it relies on engineering equivalence and performance data. Most Toxicology devices follow this clearance model.

Regulatory Peers - LGS Fluorescence Polarization Immunoassay, Theophylline

All 12
Devices cleared under the same product code (LGS) and FDA review panel - the closest regulatory comparables to K070810.
AXSYM THEOPHYLLINE II
K953016 · Abbott Laboratories · Aug 1995
TDX/TDXFLX & TDXFLX THEOPHYLLINE MONOCLONAL II
K932127 · Abbott Laboratories · Aug 1993
ABBOTT TDX/TDXFLX AND TDXFLX THEOPHYLLINE
K922991 · Abbott Laboratories · Aug 1992
COBAS FP REAGENTS FOR THEOPHYLLINE & CALIBRATORS
K871484 · Roche Diagnostic Systems, Inc. · May 1987
COBAS IMMUNOASSAY FOR THEOPHYLLINE & CAL
K843826 · Roche Diagnostic Systems, Inc. · Feb 1985